CD19 and cancer: The PPGK1-CD19 design activated the CAR T cells in a manner analogous to NALM6 across all examined target-to-effector cell ratios, hence verifying successful yeast-based simulation of CD19+ cancer cells towards the clinical Hu19-CD8ɑ-CD28-CD3ζ CAR T cell product (Fig. 5a–c).